The Intake — full feed
Every round we have collected, newest first — company, what it actually does in one plain sentence, the amount as its source reported it, and a link back to that source. The weekly summary, the takeaway and the i-Index live on the main Intake page.
314 rounds held · 17 Jul 2026 → 11 Sept 2026 · 19 collection runs
Biotech & Life Sciences
1–13 of 13- 3 Sept 2026ENA RespiratoryAUD 3m (reported)
A nasal spray that switches on the airway's own immune response to flu and other respiratory viruses, now heading into asthma trials.
- 2 Sept 2026GonGlobalAUD 1.2m (reported)
Developing inhaled fertility drugs so IVF patients do not need daily injections.
- 27 Aug 2026Adaptyv Bio€34.4m (reported)
An automated wet lab that builds and tests AI-designed proteins to order.
- 25 Aug 2026Immunobiota$5m (reported)Rumoured · not indexed
Developing an oral, non-immunosuppressive drug therapy for type 1 diabetes.
- 20 Aug 2026BowerAUD 2m (reported)
AI software that captures lab experiments in real time to build a research operating system for scientists.
- 20 Aug 2026Pixelgen Technologies€13.3m (reported)
A platform for high-throughput spatial mapping of proteins on the surface of cells.
- 18 Aug 2026Computomics€6.3m (reported)
A platform for climate-resilient plant breeding, used to develop crop varieties faster.
- 11 Aug 2026AquaNab
Develops nanoantibody treatments to prevent and treat diseases in farmed fish.
- 7 Aug 2026Mironid$46m (reported)
Biopharmaceutical company developing small-molecule drugs for a rare inherited kidney disease (ADPKD).
- 31 Jul 2026GenePlanet
Runs a genetic testing and DNA sequencing lab offering advanced genomic health tests to consumers and clinics.
- 24 Jul 2026Moa Technology€25.9m (reported)
Develops new herbicides that work on weeds that have become resistant to existing weedkillers.
- 22 Jul 2026Brenus Pharma€11m (reported)
Clinical-stage immunotherapy designed to stop hard-to-treat solid tumours coming back after treatment.
- 22 Jul 2026Immitra Bio€2.6m (reported)
Working to make gene-editing therapies that act inside the body practical and affordable to manufacture at scale.
Every figure here is what a news outlet reported, not a verified or audited number, and outlets sometimes disagree about the same round. Rounds tagged “rumoured” are unconfirmed reports and are excluded from the i-Index entirely. This page is general information — not investment advice, and not a recommendation of any company on it. Spotted something wrong? Tell us and it gets corrected.